CD33 Single Nucleotide Polymorphism Analysis for Gemtuzumab Ozogamicin (GO/Mylotarg™) Treatment Response for AML
  • Mylotarg™ has been approved by the FDA for treatment of AML
  • A single nucleotide polymorphism can predict response to Mylotarg™
  • HematoLogics has developed a molecular diagnostic test to identify patients who will benefit from treatment with Mylotarg™
  • CD33 SNP sequencing analysis will determine if the patient has a T-allele (non-responsive to Mylotarg™) or a CC-genotype (responsive to Mylotarg™)

Sample Case